Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome
Stopped Company decision
Conditions
- Small Intestinal NET
- Carcinoid Heart Disease
Interventions
- DRUG: Telotristat Ethyl
- DRUG: Lanreotide
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators